Zoetis (ZTS) Gets a Buy from Bank of America Securities

In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Zoetis (ZTS – Research Report). The company’s shares closed yesterday at $151.94.

Ryskin covers the Healthcare sector, focusing on stocks such as Illumina, Zoetis, and Idexx Laboratories. According to TipRanks, Ryskin has an average return of 3.3% and a 49.47% success rate on recommended stocks.

Zoetis has an analyst consensus of Strong Buy, with a price target consensus of $217.17, implying a 42.93% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $260.00 price target.

Based on Zoetis’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.21 billion and a net profit of $525 million. In comparison, last year the company earned a revenue of $2.04 billion and had a net profit of $461 million

Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZTS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zoetis (ZTS) Company Description:

Founded in 1952, New Jersey-based Zoetis, Inc. is the world’s largest manufacturer of medicine and vaccinations for pets and livestock in the United States and internationally. Its products are complemented by diagnostic products, genetic tests, bio devices and services.